A Phase I Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Mitiperstat

This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of mitiperstat.

开始日期2023-03-20

申办/合作机构

AstraZeneca PLC

NCT05492877

/ Completed临床2期

A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of Mitiperstat (AZD4831), for 12-24 Weeks, in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.

开始日期2022-11-14

申办/合作机构

AstraZeneca PLC

100 项与 Mitiperstat 相关的临床结果

登录后查看更多信息

100 项与 Mitiperstat 相关的转化医学

登录后查看更多信息

100 项与 Mitiperstat 相关的专利（医药）

登录后查看更多信息

项与 Mitiperstat 相关的文献（医药）

2025-11-01·Liver International

A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non‐Cirrhotic Metabolic Dysfunction‐Associated Steatohepatitis

Article

作者: Vespasiani‐Gentilucci, Umberto ; Eriksson, John ; Sunnåker, Mikael ; Challis, Benjamin ; Aurell, Malin ; Trebski, Monika ; Carter, Debra ; Bhattacharya, Chandrali S. ; Flor, Armando ; Nelander, Karin ; Whatling, Carl ; Gårdmark, Emma ; Armisen, Javier

ABSTRACT:

Background and Aims:

Neutrophil myeloperoxidase is involved in different inflammatory diseases, including metabolic dysfunction‐associated steatohepatitis (MASH). Mitiperstat is a highly potent myeloperoxidase inhibitor. This phase 2a clinical trial evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of mitiperstat in patients with non‐cirrhotic MASH.

Methods:

The study enrolled 112 adult participants with histological MASH F1–3 fibrosis and increased alanine aminotransferase (ALT) levels. Participants were randomised 1:1 to once‐daily mitiperstat 5 mg or placebo. Primary and secondary endpoints were absolute and placebo‐adjusted changes from baseline to week 12 in ALT and N‐terminal type‐III collagen propeptide (Pro‐C3) levels. Exploratory endpoints included other MASH‐related biomarkers.

Results:

At week 12, there were no significant changes versus placebo for ALT (+7.5%, p = 0.893) and Pro‐C3 (−0.9%, p = 0.396), or any other MASH‐related biomarkers. Mitiperstat was safe and well tolerated.

Conclusion:

This study does not provide proof of concept that mitiperstat 5 mg exerts an anti‐inflammatory/anti‐fibrotic effect in MASH.

Trial Registration:

ClincalTrials.gov identifier: NCT05638737

2025-09-01·MAYO CLINIC PROCEEDINGS

Acute Effects of Myeloperoxidase Inhibition on Exercise Hemodynamics in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial

Article

作者: Melenovsky, Vojtech ; Popovic, Dejana ; Borlaug, Barry A ; Burkhoff, Daniel ; Omote, Kazunori ; Reddy, Yogesh N V ; Omar, Massar

OBJECTIVE:

Myeloperoxidase (MPO) is a heme peroxidase that scavenges nitric oxide and contributes to microvascular dysfunction. Patients with heart failure and preserved ejection fraction (HFpEF) have microvascular dysfunction that leads to increased pulmonary capillary wedge pressure (PCWP). We sought to investigate whether acute MPO inhibition can reduce exertional PCWP in patients with HFpEF.

PATIENTS AND METHODS:

Between July 1, 2018, and February 24, 2022, participants with HFpEF were recruited. They underwent baseline invasive hemodynamic exercise evaluation and were then randomized, double-blind, to a single dose of the MPO inhibitor mitiperstat at 30 mg or matching placebo, after which they underwent repeated invasive hemodynamic exercise testing. The primary end point was PCWP during 20-W exercise workload.

RESULTS:

Patients with HFpEF (N=30; mean ± SD age, 70±9 years; 11 female [37%]; body mass index, 34.0 kg/m²) displayed typical hemodynamic responses to exercise prior to treatment, with PCWP increasing from 17±5 to 32±6 mm Hg with exercise and mean pulmonary artery pressure increasing from 28±9 to 49±11 mm Hg. Contrary to our hypothesis, as compared with placebo, mitiperstat treatment resulted in a higher PCWP during the second bout of exercise (-1±3 vs -4±5 mm Hg; P=.04). There was a trend for less reduction in mean pulmonary artery pressure and lower pulmonary artery compliance during exercise with mitiperstat as compared with placebo. There was no effect of mitiperstat on arterial, coronary sinus, or transcardiac uptake/release of O₂, CO₂, and lactate compared with placebo.

CONCLUSION:

Acute MPO inhibition with mitiperstat did not reduce exertional hemodynamic congestion in patients with HFpEF.

2024-12-01·BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat

Article

作者: Nelander, Karin ; Ali, Hodan ; Bhattacharya, Chandrali S. ; Genov, Diyan K. ; Pizzato, Patricia Ely ; Collén, Anna ; Trebski, Monika ; Holden, Julie ; Aurell, Malin ; Ericsson, Hans ; Heijer, Maria ; Sunnåker, Mikael

Aims:

Mitiperstat is a novel, highly potent myeloperoxidase inhibitor being evaluated in patients with cardio‐metabolic disease (phase 2). These patients often have impaired renal function, which may affect mitiperstat pharmacokinetics. This study assessed mitiperstat pharmacokinetics, safety and tolerability in participants with severe renal impairment and normal renal function, to inform inclusion of participants with estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 in phase 3.

Methods:

Participants with severe renal impairment (eGFR ≥15 and <30 mL/min/1.73 m2) who were not on dialysis (n = 10) and group‐matched controls (eGFR ≥90 mL/min/1.73 m2; n = 10) received a single mitiperstat 2.5 mg oral tablet. Blood samples were collected at intervals for 2 weeks and urine samples for 24 h post‐dose.

Results:

Total apparent mitiperstat clearance was 10.83 L/h in the severe renal impairment cohort and 25.62 L/h in the control cohort. The area under the plasma concentration–time curve was 2.37‐fold higher (90% confidence interval [CI]: 1.79, 3.12) in the severe renal impairment cohort than in the control cohort, with longer elimination half‐life and similar maximum concentration. Non‐renal clearance was similar between the cohorts.

Conclusions:

Mitiperstat apparent clearance was approximately twofold lower in individuals with severe renal impairment than in those with normal renal function. Lower clearance was driven by reduced renal clearance; non‐renal clearance was similar. Mitiperstat was generally well tolerated by participants with severe renal impairment and normal renal function. These findings, together with efficacy and safety/tolerability data from phase 2b, will guide the dosing regimen for phase 3.

项与 Mitiperstat 相关的新闻（医药）

2025-02-06

·EndPoints

AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal

AstraZeneca has terminated all development of vemircopan, the oral factor D inhibitor it acquired through the deal for Alexion in 2021. The UK major recorded an impairment charge of $753 million as a result, according to 2024 earnings that were reported on Thursday. Development of vemircopan for paroxysmal nocturnal hemoglobinuria was halted in November 2023, but now the drug is being abandoned completely. A Phase 2 trial in lupus nephritis or IgA nephropathy, and an early-stage trial in impaired hepatic function, have also been discontinued for lack of efficacy. Marc Dunoyer, the CEO of AstraZeneca’s rare disease unit, said it “is not immune to the odds of the industry, where not all of the pioneering work that you do is going to work.” He added that the decision to drop vemircopan was based on standard criteria, namely its benefits and risks, as well as the competitive situation. Despite the loss, AstraZeneca CEO Pascal Soriot told reporters at a London event: “I can say with no hesitation, the Alexion acquisition was a fantastic acquisition.” AstraZeneca also took a $165 million impairment on FPI-2059, a Phase 1-stage radioligand that was scrapped. The drug was part of last year’s purchase of Fusion Pharmaceuticals. FPI-2059 is a lutetium-labeled small molecule targeting neurotensin receptor 1 which Alexion itself licensed from Ipsen in 2021. Other radioligands remain in development. AstraZeneca’s lead radioconjugate, FPI-2265, is a beta-emitting, PSMA-targeting product. Data on its Phase 2 prostate cancer trial could come in the second half of this year. “The field of radioconjugates is a little behind the field of ADCs at the moment, but it holds great potential,” AstraZeneca’s oncology R&D leader Susan Galbraith said at the earnings event. Elsewhere, AstraZeneca shut down: The company also reiterated the termination of a mid-stage study of an orexin 1 receptor antagonist, AZD4041, in opioid use disorder. The shuttering emerged in November , with a spokesperson telling Endpoints News the move was due to “a potential drug-drug interaction.” It appears that AstraZeneca will put its long-acting amylin asset AZD6234 into a new Phase 2b trial in obesity, in combination with the GLP-1/glucagon agonist AZD9550. According to a record on the EU’s trial database , the trial will end in the middle of next year. AZD6234 is already in a separate mid-stage monotherapy trial, which could yield data late this year. The company claimed it is heading into an “unprecedented catalyst-rich 2025,” citing a handful of late-stage trials for indication expansions, such as the AVANZAR study of Datroway in first-line non-small cell lung cancer. David Fredrickson, the leader of the company’s oncology business, affirmed his confidence in the ADC despite its stumbles in late-stage trials in both lung and breast cancers. “We’ve been able to apply the lessons that we’ve learned from the previous Phase 3 and Phase 2 studies that have read out so far to the frontline AVANZAR study,” Fredrickson said. The trial is enriched for the non-squamous population “because we think that’s the opportunity to see the most benefit for Datroway in the front line.” Combining the drug with the checkpoint inhibitor Imfinzi could also increase the chances of success, he said. Other major Phase 3 readouts will come for products still in earlier stages, such as the SERD camizestrant in breast cancer, baxdrostat in hypertension, and eneboparatide in hypoparathyroidism.

临床1期临床2期并购临床3期

2025-01-22

·PRNewswire

Chronic Heart Failure Market to Observe Stunning Growth at a CAGR of 10% by 2034 Owing to Strong Uptake of Entresto and approved SGLT2 Inhibitors along with Emergence of New Class of Therapies | DelveInsight

Several leading classes of therapies are exploring diverse mechanisms of action to treat CHF, including SGLT2 inhibitors, cardiac myosin activators, myeloperoxidase inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, cell therapies, and more. This growing focus is expected to drive the chronic heart failure market forward. In summary, the existing blockbuster therapies such as Entresto, recently approved SGLT2 inhibitors, and Soluble guanylate cyclase (sGC) stimulators, along with emerging cell therapies, peptides, monoclonal antibodies, and small molecules, together have the potential to drive the existing market along with securing a significant market share upon introduction of new entrants to the CHF treatment landscape. LAS VEGAS, Jan. 22, 2025 /PRNewswire/ -- DelveInsight's Chronic Heart Failure Market Insights report includes a comprehensive understanding of current treatment practices, chronic heart failure emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Chronic Heart Failure Market Report According to DelveInsight's analysis, the market size for chronic heart failure was found to be approximately USD 5.5 billion in the US in 2023. Among the 7MM, the US contributed the largest market share of the total CHF market size and will continue to experience a steep rise in the market size throughout the forecast period. As per DelveInsight's estimate, the total diagnosed prevalent cases of CHF in the 7MM were approximately 20 million in 2023. Heart failure with preserved ejection fraction (HFpEF) contributed to most of the cases. Within class-specific diagnosed prevalence of Heart failure, NYHA class II and class III contribute the maximum. Established chronic heart failure companies with approved therapies in the market are Novartis, Otsuka, Boehringer Ingelheim/Eli Lilly, Bayer/Merck, Amgen/Servier, scPharmaceuticals, and Lexicon Pharmaceuticals/Viatris. In addition, Daiichi Sankyo and American Regent are targeting adult patients with heart failure who are iron deficient. Among all the approved therapies, Novartis and Otsuka's Entresto, approved since 2015 in the US, is still the leading therapy generating more than USD 4 billion in the 7MM in 2023. Among, Eli Lilly's Jardiance and AstraZeneca's Farxiga, both SGLT2 inhibitors, Farxiga is the leading prescribed SGLT2 inhibitor globally by volume Leading chronic heart failure companies developing emerging therapies, such as Cytokinetics, Bayer, Eli Lilly, BioCardia, Mesoblast, Tenax Therapeutics, Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Intra-Cellular Therapies, Cardurion Pharmaceuticals, Rivus Pharmaceuticals, and others are developing novel chronic heart failure drugs that can be available in the chronic heart failure market in the coming years. The promising chronic heart failure therapies in the pipeline include Omecamtiv Mecarbil, KERENDIA (finerenone), Tirzepatide (LY3298176), CardiAMP Cell Therapy, Ziltivekimab (NN6018), REVASCOR (rexlemestrocel-L), Levosimendan (TNX-103), Semaglutide, Balcinrenone (AZD9977) + dapagliflozin, Mitiperstat (AZD4831), Vicadrostat (BI 690517) + Empagliflozin, Cimlanod (CXL-1427/BMS-986231), Lenrispodun (ITI - 214), CRD-740, HU6, and others. In October 2024, Viatris entered into an exclusive licensing agreement with Lexicon Pharmaceuticals for INPEFA (sotagliflozin) in all markets outside of the US and EU. In September 2024, Bayer presented the late-breaking data of Phase III FINE-HEART findings of KERENDIA (finerenone) during a Hot Line session at the European Society of Cardiology (ESC) Congress 2024. In May 2024, Eli Lilly and Company committed an additional USD 5.3 billion manufacturing investment in the company's newest Indiana site to boost API production for tirzepatide and pipeline medicines. AstraZeneca expects the data of the Phase III BalanceD-HF trial of balcinrenone (AZD9977) + dapagliflozin for heart failure in 2025. Discover which therapies are expected to grab the major chronic heart failure market share @ Chronic Heart Failure Market Report Chronic Heart Failure Overview Chronic heart failure is a long-term condition in which the heart's ability to pump blood efficiently is reduced, leading to inadequate circulation of oxygen and nutrients to meet the body's needs. The primary causes of CHF include coronary artery disease, high blood pressure, diabetes, cardiomyopathy, valvular heart disease, and previous heart attacks. Lifestyle factors like obesity, smoking, excessive alcohol consumption, and a sedentary lifestyle can also contribute to its development. The symptoms of CHF vary in severity and may include persistent fatigue, shortness of breath, swelling in the legs, ankles, or abdomen, rapid or irregular heartbeat, and difficulty exercising. Advanced cases can lead to severe fluid retention, wheezing, and an inability to carry out daily activities. Diagnosis typically involves a comprehensive medical history review and a physical examination, followed by tests like an ECG to assess heart rhythm, echocardiography to evaluate heart structure and function, blood tests, chest X-rays, and stress tests. Early diagnosis and management are crucial to improving quality of life and preventing complications. Chronic Heart Failure Epidemiology Segmentation The chronic heart failure epidemiology section provides insights into the historical and current chronic heart failure patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The chronic heart failure market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of Heart Failure Gender-specific Cases of Heart Failure Ejection Fraction-specific Cases of Heart Failure New York Heart Association (NYHA) Class-specific Cases of Heart Failure Type-specific Cases of Heart Failure Age-specific Cases of Heart Failure Chronic Heart Failure Treatment Market Current treatments for heart failure primarily rely on angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics. Additional therapies, such as aldosterone antagonists, amiodarone, antiplatelets, anticoagulants, calcium channel blockers, and nitrates, are also utilized in managing the condition. Most treatment regimens involve a combination of therapies, with beta-blockers being among the most commonly prescribed. Among the approved treatments, Novartis' ENTRESTO has emerged as a leading drug in the congestive heart failure market. Initially slow to gain traction, ENTRESTO has become one of Novartis' key growth drivers, with revenue expected to increase in the coming years. Following its approval for use in patients with preserved ejection fraction, ENTRESTO's market presence has grown significantly. However, ENTRESTO faces growing competition. The entry of new drugs, including SGLT2 inhibitors (such as FARXIGA and JARDIANCE) and VERQUVO, poses a challenge to ENTRESTO's dominance. Additionally, Novartis is set to lose ENTRESTO's exclusivity in the United States in 2025, raising the risk of generic competition. The company is actively engaged in several patent lawsuits to protect its position. SGLT2 inhibitors have also gained a foothold in the CHF market. Although FARXIGA and JARDIANCE are established drugs, they are relatively new in this therapeutic area. The outlook for SGLT2 inhibitors in heart failure is promising, but AstraZeneca and Lilly/Boehringer will have limited time to solidify their positions, as FARXIGA's US patent expires in 2025 and JARDIANCE's in 2028. The recently approved SGLT2 inhibitor sotagliflozin may face challenges in capturing market share from these established treatments. To know more about chronic heart failure treatment guidelines, visit @ Chronic Heart Failure Management Chronic Heart Failure Pipeline Therapies and Key Companies Omecamtiv Mecarbil: Cytokinetics KERENDIA (finerenone): Bayer Tirzepatide (LY3298176): Eli Lilly and Company CardiAMP Cell Therapy: BioCardia Ziltivekimab (NN6018): Novo Nordisk REVASCOR (rexlemestrocel-L): Mesoblast Levosimendan (TNX-103): Tenax Therapeutics Semaglutide: Novo Nordisk Balcinrenone (AZD9977) + dapagliflozin: AstraZeneca Mitiperstat (AZD4831): AstraZeneca Vicadrostat (BI 690517) + Empagliflozin: Boehringer Ingelheim Cimlanod (CXL-1427/BMS-986231): Bristol Myers Squibb Lenrispodun (ITI - 214): Intra-Cellular Therapies CRD-740: Cardurion Pharmaceuticals HU6: Rivus Pharmaceuticals Discover more about chronic heart failure drugs in development @ Chronic Heart Failure Clinical Trials Chronic Heart Failure Market Dynamics The chronic heart failure market dynamics are expected to change in the coming years. An increasing prevalence of cardiovascular diseases, fueled by aging populations and lifestyle-related risk factors such as obesity, hypertension, and diabetes, has significantly raised the demand for effective CHF treatments. Advances in medical technology, including innovative drug therapies, cardiac devices, and regenerative medicine, are expanding treatment options and improving patient outcomes. Growing awareness about heart health and early diagnosis, supported by government and non-government initiatives, is also boosting market expansion. Additionally, the rising focus on personalized medicine and the development of therapies targeting the underlying molecular mechanisms of CHF are creating lucrative opportunities. The increasing healthcare expenditure and the availability of reimbursement policies in developed and emerging economies further bolster the market's growth trajectory. Furthermore, potential therapies are being investigated for the treatment of chronic heart failure, and it is safe to predict that the treatment space will significantly impact the chronic heart failure market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the chronic heart failure market in the 7MM. However several factors may impede the growth of the chronic heart failure market. A key challenge is the underdiagnosis and delayed recognition of CHF due to overlapping symptoms with other conditions and the lack of widespread access to advanced diagnostic tools in many regions. Economic constraints, particularly in low- and middle-income countries, limit patient access to costly therapies, including advanced drugs and devices. Additionally, adherence to treatment regimens remains low due to the complexity of management protocols and the long-term nature of care, leading to suboptimal outcomes. Regulatory hurdles and lengthy approval processes for novel therapies further impede the introduction of innovative treatments. Finally, a limited understanding among general practitioners about newer guidelines and therapies reduces the referral rates to specialists, creating gaps in patient care. Addressing these barriers requires concerted efforts in education, affordability, and healthcare infrastructure. Scope of the Chronic Heart Failure Market Report Therapeutic Assessment: Chronic Heart Failure current marketed and emerging therapies Chronic Heart Failure Market Dynamics: Key Market Forecast Assumptions of Emerging Chronic Heart Failure Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Chronic Heart Failure Market Access and Reimbursement Download the report to understand which factors are driving chronic heart failure market trends @ Chronic Heart Failure Market Trends Table of Contents Related Reports Chronic Heart Failure Epidemiology Forecast Chronic Heart Failure Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the chronic heart failure epidemiology trends. Chronic Heart Failure Pipeline Chronic Heart Failure Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CHF companies, including Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, Ionis Pharmaceuticals, Berlin Cures, CardioCell, Help Therapeutics, Eli Lilly and Company, Chong Kun Dang Pharmaceutical, Antlia Biosciences, Cardiol Therapeutics, among others. Acute Coronary Syndrome Market Acute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ACS companies, including Novartis, Boehringer Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra , among others. Acute Coronary Syndrome Pipeline Acute Coronary Syndrome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute coronary syndrome companies, including Janssen Research & Development, LLC, DalCor Pharmaceuticals, Hyloris Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期上市批准引进/卖出

100 项与 Mitiperstat 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
射血分数保留型心力衰竭	临床3期	美国	AstraZeneca PLC	2021-06-30
射血分数保留型心力衰竭	临床3期	日本	AstraZeneca PLC	2021-06-30
射血分数保留型心力衰竭	临床3期	澳大利亚	AstraZeneca PLC	2021-06-30
射血分数保留型心力衰竭	临床3期	比利时	AstraZeneca PLC	2021-06-30
射血分数保留型心力衰竭	临床3期	巴西	AstraZeneca PLC	2021-06-30
射血分数保留型心力衰竭	临床3期	保加利亚	AstraZeneca PLC	2021-06-30
射血分数保留型心力衰竭	临床3期	加拿大	AstraZeneca PLC	2021-06-30
射血分数保留型心力衰竭	临床3期	捷克	AstraZeneca PLC	2021-06-30
射血分数保留型心力衰竭	临床3期	丹麦	AstraZeneca PLC	2021-06-30
射血分数保留型心力衰竭	临床3期	法国	AstraZeneca PLC	2021-06-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05638737 (Pubmed \| Liver Int)	临床2期	代谢功能障碍相关脂肪性肝炎	112	Mitiperstat 5 mg	艱淵憲積鬱襯願餘顧簾(壓鹹顧淵積膚顧簾淵蓋) = 窪繭襯製構醖艱壓糧憲觸製築鑰蓋憲繭壓願繭 (夢製願醖艱積襯壓廠艱 )	不佳	2025-11-01
				Placebo	艱淵憲積鬱襯願餘顧簾(壓鹹顧淵積膚顧簾淵蓋) = 糧鑰獵選製衊獵蓋鏇簾觸製築鑰蓋憲繭壓願繭 (夢製願醖艱積襯壓廠艱 )
NCT05492877 (CRESCENDO, CTgov)	临床2期	慢性阻塞性肺疾病	381	Placebo	獵齋蓋鹹遞廠鬱鹹鏇襯 = 製膚夢膚窪範衊簾網鑰膚鬱窪顧製選築鹽繭鹹 (齋膚蓋糧鏇廠顧鹽積鑰, 糧廠艱齋範廠艱鏇簾鬱 ~ 艱選構蓋窪築窪窪鹹齋) 更多	-	2025-08-29
NCT04986202 (ENDEAVOR, CTgov)	临床2/3期	射血分数保留型心力衰竭	711	AZD4831 (AZD4831 2.5 mg)	壓願顧壓網獵廠獵蓋鹽(窪齋築顧遞膚餘窪網蓋) = 餘膚艱醖構鹹鏇觸齋壓齋襯襯選簾鑰構廠觸鹹 (鬱鑰窪顧淵鑰遞衊鬱鏇, 築製願膚構蓋範鏇餘夢 ~ 鑰餘淵範鑰餘壓糧網廠) 更多	-	2025-08-27
				AZD4831 (AZD4831 5 mg)	壓願顧壓網獵廠獵蓋鹽(窪齋築顧遞膚餘窪網蓋) = 憲鹹襯糧鹽窪鑰網觸蓋齋襯襯選簾鑰構廠觸鹹 (鬱鑰窪顧淵鑰遞衊鬱鏇, 蓋願夢蓋鹽獵蓋顧憲蓋 ~ 淵構鑰憲憲觸廠廠觸廠) 更多
NCT05638737 (COSMOS, CTgov)	临床2期	代谢功能障碍相关脂肪性肝炎 \| 纤维化	112	Placebo	壓積憲淵簾餘網積窪膚(醖夢築鏇蓋壓鏇獵襯鏇) = 蓋築製醖膚憲齋獵鑰願繭願糧築鏇獵艱淵積鬱 (鹹糧糧糧製廠齋範齋觸, 獵夢願夢顧鑰憲膚鏇選 ~ 繭範網壓選窪網淵構鏇) 更多	-	2025-07-09
NCT03611153 (CTgov)	临床1/2期	射血分数保留型心力衰竭	30	AZD4831 (AZD4831 Oral Myeloperoxidase Inhibitor)	蓋壓鬱窪製蓋衊衊衊遞(醖築網遞鹹鏇鹹範壓鑰) = 鹽顧鏇膚築鹹衊鏇夢遞觸壓網觸餘醖繭網膚衊 (範選鹽簾壓繭遞衊鏇蓋, 3) 更多	-	2025-01-08
				Placebo oral capsule (Placebo)	蓋壓鬱窪製蓋衊衊衊遞(醖築網遞鹹鏇鹹範壓鑰) = 鏇遞鬱醖選範齋築遞鑰觸壓網觸餘醖繭網膚衊 (範選鹽簾壓繭遞衊鏇蓋, 5) 更多
NCT04232345 (Pubmed \| Clin Drug Investig)	临床1期	-	32	Mitiperstat 2.5 mg	觸艱憲網壓襯繭築廠廠(壓鬱窪醖網壓遞鬱衊願) = a few events of maculopapular rash 製製衊願醖範壓夢壓糧 (願餘遞積築選餘鏇夢壓 ) 更多	积极	2024-11-01
				Mitiperstat 5 mg
NCT03756285 (SATELLITE, CTgov)	临床2期	射血分数保留型心力衰竭	41	AZD4831 (AZD4831)	觸網築簾獵衊範鹽衊鏇(壓鏇夢選鹹築淵廠鑰鏇) = 醖鹽顧膚遞窪壓鹹蓋艱餘壓憲積膚壓積鹹願築 (蓋鬱艱鏇獵鬱範範遞廠, 顧夢範衊淵醖簾膚鬱鹹 ~ 遞艱艱構蓋夢蓋網鹽遞) 更多	-	2021-07-19
				Placebo (Placebo)	觸網築簾獵衊範鹽衊鏇(壓鏇夢選鹹築淵廠鑰鏇) = 艱構遞構鏇獵製觸蓋選餘壓憲積膚壓積鹹願築 (蓋鬱艱鏇獵鬱範範遞廠, 壓齋餘積簾網範鏇膚淵 ~ 鬱壓簾艱鹹夢願衊膚獵) 更多